FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137130305> ?p ?o ?g. }

• W2137130305 abstract "Anti-malarial drug resistance in Plasmodium falciparum in India has historically travelled from northeast India along the Myanmar border. The treatment policy for P. falciparum in the region was, therefore, changed from chloroquine to artesunate (AS) plus sulphadoxine-pyrimethamine (SP) in selected areas in 2005 and in 2008 it became the first-line treatment. Recognizing that resistance to the partner drug can limit the useful life of this combination therapy, routine in vivo and molecular monitoring of anti-malarial drug efficacy through sentinel sites was initiated in 2009.Between May and October 2012, 190 subjects with acute uncomplicated falciparum malaria were enrolled in therapeutic efficacy studies in the states of Arunachal Pradesh, Tripura, and Mizoram. Clinical and parasitological assessments were conducted over 42 days of follow-up. Multivariate analysis was used to determine risk factors associated with treatment failure. Genotyping was done to distinguish re-infection from recrudescence as well as to determine the prevalence of molecular markers of antifolate resistance among isolates.A total of 169 patients completed 42 days of follow-up at three sites. The crude and PCR-corrected Kaplan-Meier survival estimates of AS + SP were 60.8% (95% CI: 48.0-71.4) and 76.6% (95% CI: 64.1-85.2) in Gomati, Tripura; 74.6% (95% CI: 62.0-83.6) and 81.7% (95% CI: 69.4-89.5) in Lunglei, Mizoram; and, 59.5% (95% CI: 42.0-73.2) and 82.3% (95% CI: 64.6-91.6) in Changlang, Arunachal Pradesh. Most patients with P. falciparum cleared parasitaemia within 24 hours of treatment, but eight, including three patients who failed treatment, remained parasitaemic on day 3. Risk factors associated with treatment failure included age < five years, fever at the time of enrolment and AS under dosing. No adverse events were reported. Presence of dhfr plus dhps quintuple mutation was observed predominantly in treatment failure samples.AS + SP treatment failure was widespread in northeast India and exceeded the threshold for changing drug policy. Based on these results, in January 2013 the expert committee of the National Vector Borne Disease Control Programme formulated the first subnational drug policy for India and selected artemether plus lumefantrine as the new first-line treatment in the northeast. Continued monitoring of anti-malarial drug efficacy is essential for effective malaria control." @default.
• W2137130305 created "2016-06-24" @default.
• W2137130305 creator A5018231474 @default.
• W2137130305 creator A5023145210 @default.
• W2137130305 creator A5033378103 @default.
• W2137130305 creator A5051972045 @default.
• W2137130305 creator A5061398968 @default.
• W2137130305 creator A5064354766 @default.
• W2137130305 creator A5064722195 @default.
• W2137130305 creator A5067857554 @default.
• W2137130305 creator A5068017030 @default.
• W2137130305 creator A5070462000 @default.
• W2137130305 creator A5075340343 @default.
• W2137130305 creator A5081401311 @default.
• W2137130305 creator A5083289823 @default.
• W2137130305 date "2014-07-22" @default.
• W2137130305 modified "2023-10-18" @default.
• W2137130305 title "Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India" @default.
• W2137130305 cites W1966834016 @default.
• W2137130305 cites W2005705112 @default.
• W2137130305 cites W2010067521 @default.
• W2137130305 cites W2013267325 @default.
• W2137130305 cites W2029359792 @default.
• W2137130305 cites W2040095486 @default.
• W2137130305 cites W2040713555 @default.
• W2137130305 cites W2048102298 @default.
• W2137130305 cites W2049183597 @default.
• W2137130305 cites W2066719680 @default.
• W2137130305 cites W2123887868 @default.
• W2137130305 cites W2124634096 @default.
• W2137130305 cites W2126566626 @default.
• W2137130305 cites W2132093894 @default.
• W2137130305 cites W2134381091 @default.
• W2137130305 cites W2135926190 @default.
• W2137130305 cites W2139324809 @default.
• W2137130305 cites W2161311583 @default.
• W2137130305 cites W2161853348 @default.
• W2137130305 doi "https://doi.org/10.1186/1475-2875-13-284" @default.
• W2137130305 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4127069" @default.
• W2137130305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25052385" @default.
• W2137130305 hasPublicationYear "2014" @default.
• W2137130305 type Work @default.
• W2137130305 sameAs 2137130305 @default.
• W2137130305 citedByCount "60" @default.
• W2137130305 countsByYear W21371303052015 @default.
• W2137130305 countsByYear W21371303052016 @default.
• W2137130305 countsByYear W21371303052017 @default.
• W2137130305 countsByYear W21371303052018 @default.
• W2137130305 countsByYear W21371303052019 @default.
• W2137130305 countsByYear W21371303052020 @default.
• W2137130305 countsByYear W21371303052021 @default.
• W2137130305 countsByYear W21371303052022 @default.
• W2137130305 countsByYear W21371303052023 @default.
• W2137130305 crossrefType "journal-article" @default.
• W2137130305 hasAuthorship W2137130305A5018231474 @default.
• W2137130305 hasAuthorship W2137130305A5023145210 @default.
• W2137130305 hasAuthorship W2137130305A5033378103 @default.
• W2137130305 hasAuthorship W2137130305A5051972045 @default.
• W2137130305 hasAuthorship W2137130305A5061398968 @default.
• W2137130305 hasAuthorship W2137130305A5064354766 @default.
• W2137130305 hasAuthorship W2137130305A5064722195 @default.
• W2137130305 hasAuthorship W2137130305A5067857554 @default.
• W2137130305 hasAuthorship W2137130305A5068017030 @default.
• W2137130305 hasAuthorship W2137130305A5070462000 @default.
• W2137130305 hasAuthorship W2137130305A5075340343 @default.
• W2137130305 hasAuthorship W2137130305A5081401311 @default.
• W2137130305 hasAuthorship W2137130305A5083289823 @default.
• W2137130305 hasBestOaLocation W21371303051 @default.
• W2137130305 hasConcept C104317684 @default.
• W2137130305 hasConcept C114851261 @default.
• W2137130305 hasConcept C126322002 @default.
• W2137130305 hasConcept C135763542 @default.
• W2137130305 hasConcept C203014093 @default.
• W2137130305 hasConcept C2776120307 @default.
• W2137130305 hasConcept C2777035104 @default.
• W2137130305 hasConcept C2778048844 @default.
• W2137130305 hasConcept C2778059366 @default.
• W2137130305 hasConcept C2778301690 @default.
• W2137130305 hasConcept C2778371730 @default.
• W2137130305 hasConcept C31467283 @default.
• W2137130305 hasConcept C42972112 @default.
• W2137130305 hasConcept C55493867 @default.
• W2137130305 hasConcept C71924100 @default.
• W2137130305 hasConcept C86803240 @default.
• W2137130305 hasConcept C89423630 @default.
• W2137130305 hasConceptScore W2137130305C104317684 @default.
• W2137130305 hasConceptScore W2137130305C114851261 @default.
• W2137130305 hasConceptScore W2137130305C126322002 @default.
• W2137130305 hasConceptScore W2137130305C135763542 @default.
• W2137130305 hasConceptScore W2137130305C203014093 @default.
• W2137130305 hasConceptScore W2137130305C2776120307 @default.
• W2137130305 hasConceptScore W2137130305C2777035104 @default.
• W2137130305 hasConceptScore W2137130305C2778048844 @default.
• W2137130305 hasConceptScore W2137130305C2778059366 @default.
• W2137130305 hasConceptScore W2137130305C2778301690 @default.
• W2137130305 hasConceptScore W2137130305C2778371730 @default.
• W2137130305 hasConceptScore W2137130305C31467283 @default.
• W2137130305 hasConceptScore W2137130305C42972112 @default.
• W2137130305 hasConceptScore W2137130305C55493867 @default.
• W2137130305 hasConceptScore W2137130305C71924100 @default.

• next